A childhood leukemia diagnosis does not shrink because a national fundraising total later clears $300 million. Jackson Trinh was seven when he was diagnosed with B-cell acute lymphoblastic leukemia and then spent more than two years in treatment, before becoming a National Youth Ambassador for Hyundai Hope on Wheels.
That record comes from WDEF, which also reported that he is in remission and serves in the ambassador role. The remission line is not dated, so it is not a November medical update. KENS 5 has a Healthy SA video.
What San Antonio can actually name
The local sum with investigators attached is $500,000. UT Health San Antonio said Hyundai Hope on Wheels presented two grants totaling that amount for childhood cancer research there. The grants were announced on September 24 and presented during a ceremony that day.
A $400,000 Hope Scholar Grant went to pediatric oncologist Shafqat Shah, MD, and Manjeet K. Rao, PhD, for research on medulloblastoma. A separate $100,000 Impact Grant went to pediatric oncologist Gail Tomlinson, MD, PhD, for research on childhood cancer survivorship. One award follows a brain tumor. The other follows what treatment leaves behind.
A national total, still partly a plan
On April 1, Hyundai Motor Group said Hope on Wheels had surpassed $303 million in lifetime giving to childhood cancer research since its founding in 1998. The program is supported by Hyundai Motor America and more than 855 U.S. dealers.
For 2026, Hyundai said it planned to award more than $29 million in grants across North America, including $26 million in the United States and $3 million in Canada. Planned is the operative word. That announcement does not establish that every proposed grant was ultimately awarded. Next to a nine-figure lifetime total, San Antonio's documented $500,000 is a delivery with names on it.
The 4% line is not a line item
The claim that less than 4% of federal cancer-research funding goes to children travels as if Congress had written it into a budget. Alex's Lemonade Stand Foundation says the "less than 4%" figure is an estimate of the share of the National Cancer Institute budget, not a formal earmark. It comes from analyses of funded grants and can change with the method used to count them.
A separate measure, in the 2025 AACR Pediatric Cancer Progress Report, found that pediatric cancer research accounted for less than 5% of all cancer research output over the past decade, counted by publications. Budget share and publication share are not the same number. Neither is a set-aside.
Survival rose; the estimates do not match
The American Childhood Cancer Organization estimates that 15,780 U.S. children from birth through age 19 are diagnosed with cancer each year. ACCO also says childhood leukemia diagnoses have increased by about 35% over the past 40 years, and it describes the overall five-year survival rate as close to 80%.
The American Association for Cancer Research uses another range: five-year survival rose from around 58% to 68% in the 1970s to 83% to 88% in recent years. Its 2025 progress report is tighter for the decades it measures, moving from 63.1% in the 1970s to 85.2% in the 2010s. The direction is the same. The percentages are not interchangeable, and they should stay attached to the organization that published them.
That inaugural AACR report highlighted advances in diagnosis and surveillance, personalized treatments, and work to reduce long-term treatment-related harm. Tomlinson's survivorship grant sits in the last of those. Shah and Rao's medulloblastoma study sits in the treatment science the larger checks are supposed to fund. For 2026, the North American grant total remains a plan announced in April. San Antonio's named piece of the program is the $400,000 and the $100,000 already on the record.
